- Home
- MVIS vs NMRA Comparison
MVIS vs NMRA Comparison
Compare MVIS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- NMRA
- Stock Information
- Founded
- MVIS 1993
- NMRA 2019
- Country
- MVIS United States
- NMRA United States
- Employees
- MVIS N/A
- NMRA N/A
- Industry
- MVIS Industrial Machinery/Components
- NMRA
- Sector
- MVIS Technology
- NMRA
- Exchange
- MVIS Nasdaq
- NMRA Nasdaq
- Market Cap
- MVIS 403.3M
- NMRA 424.4M
- IPO Year
- MVIS 1996
- NMRA 2023
- Fundamental
- Price
- MVIS $0.99
- NMRA $2.20
- Analyst Decision
- MVIS Strong Buy
- NMRA Buy
- Analyst Count
- MVIS 3
- NMRA 8
- Target Price
- MVIS $2.50
- NMRA $7.57
- AVG Volume (30 Days)
- MVIS 6.1M
- NMRA 1.9M
- Earning Date
- MVIS 11-11-2025
- NMRA 11-06-2025
- Dividend Yield
- MVIS N/A
- NMRA N/A
- EPS Growth
- MVIS N/A
- NMRA N/A
- EPS
- MVIS N/A
- NMRA N/A
- Revenue
- MVIS $2,635,000.00
- NMRA N/A
- Revenue This Year
- MVIS N/A
- NMRA N/A
- Revenue Next Year
- MVIS $857.46
- NMRA N/A
- P/E Ratio
- MVIS N/A
- NMRA N/A
- Revenue Growth
- MVIS N/A
- NMRA N/A
- 52 Week Low
- MVIS $0.80
- NMRA $0.61
- 52 Week High
- MVIS $1.95
- NMRA $11.57
- Technical
- Relative Strength Index (RSI)
- MVIS 42.63
- NMRA 41.50
- Support Level
- MVIS $0.88
- NMRA $2.55
- Resistance Level
- MVIS $1.07
- NMRA $2.78
- Average True Range (ATR)
- MVIS 0.09
- NMRA 0.26
- MACD
- MVIS -0.00
- NMRA -0.09
- Stochastic Oscillator
- MVIS 52.69
- NMRA 10.56
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.